Innovation projects

Innovation projects

The type of high-risk/high-gain research at the frontiers of knowledge that the ERC promotes often generates unexpected or new opportunities for commercial and societal applications. The ERC is committed to ensure the full exploitation of the excellent, useful ideas it funds. The Proof of Concept funding helps ERC grant-holders bridge the gap between their research and the earliest stage of a marketable innovation.

 

This programme contributes for R&D of excellence in research centres through the engagement of highly qualified human resources as technical support for R&D+i activities, thus maximising the potential of the existing infrastructures. It also promotes the participation of these institutions in European projects.

 

A collaborative project on brain cancer run by the IRB Barcelona and the Vall d’Hebron Institute of Oncology (VHIO) has received one of the funding concessions of the first call of the “Prova’t” programme, specific for Research Centres of Catalonia (CERCA) and funded by the “Generalitat de Catalunya” and ERDF resources.

Launched by the Botín Foundation, the “Mind the Gap” Technology Transfer Investment Programme supports the development of products and services that arise from lab bench results. IRB Barcelona has been awarded two “Mind the Gap” projects: “COLOSTAGE”, which is led by Drs. Eduard Batlle and Elena Sancho and aims to develop a diagnostic test for patients at risk of metastasis, and “NOSTRUM DRUG DISCOVERY”, a drug design platform headed by Dr. Modesto Orozco. The IRB Barcelona projects, two of the three chosen by the Foundation in 2012, will receive 500,000 euros each, as well as management, coordination and consulting support for two years.

BiomedTec is an IRB Barcelona internal programme supported by the Obra Social la Caixa and devoted to validate early-stage technologies from all disciplines. The development of the BiomedTec programme will foster the transfer of scientific results to the market, thus improving the quality of life of patients with cancer.

The first call was in 2012 and devoted to cancer. Due to the success of this first call, applications were broadened to all therapeutic areas. From the second call onwards it was officially denominated BiomedTec.

The Innovation Department is working to assure the continuation of the programme for the forecoming years.

IRB Barcelona Spin offs

Spin offs

Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2011 with the goal of developing biomarkers that predict bone metastasis to improve the cancer patient’s quality of life.

Iproteos is a biotechnology company focused on the research and development of new therapeutic strategies based on peptidic protease inhibition. Iproteos is developing peptidic protease inhibitors for the treatment of CNS diseases.

Omnia Molecular (Omnia) designs and develops antiinfectives targeted at difficult-to-treat infections. Lead compounds are synthesized and optimized using a proprietary technology platform and are proven effective in several biological assays. Final proof of concept is conducted in animal infection models.

News

17 Dec 2014

Spain will become a full member of ELIXIR, the European bioinformatics infrastructure created to optimise biological data obtained from life sciences research.

12 Dec 2014

Coinciding with the announcement by the WHO about a 50% decrease in number of cases of malaria, TV3 also explains IRB’s discovery of compounds that eliminate malaria in mice.

12 Dec 2014

“La Sexta Columna” television programme has broadcasted a report about the initiative taken by families with relatives that suffer from Friedreich’s Ataxia, a rare illness with no cure.

11 Dec 2014

Cadena Ser radio, like other national and international media, has reported on the results obtained by Lluís Ribas’s team on new borrelidin-based compounds to combat the malaria-causing parasite

Collaborations with Private Entities

Licensing Opportunities

Protease resistant peptide shuttles able to actively deliver drugs across the blood-brain barrier (Ref. IRB_016)
Novel protease resistant peptide shuttles able to cross the blood-brain barrier (BBB) by binding to a specific brain receptor. They are able to carry a wide variety of large and small molecules as cargos.

 

Testimonial

Contact

Cristina Horcajada
Head of Innovation
Tel: +34 93 40 31193